Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.55 |
| ▸ | CDK2 | P24941 | 9/20 | 0.55 |
| ▸ | CCND3 | P30281 | 9/20 | 0.53 |
| ▸ | CDK1 | P06493 | 7/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | CDK7 | P50613 | 3/20 | 0.52 |
| ▸ | CDK9 | P50750 | 3/20 | 0.52 |
| ▸ | CCND1 | P24385 | 8/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | STK16 | O75716 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669654 | 1.00 | CDK4 (0.55) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19836706 | 0.92 | CDK4 (0.54) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19836272 | 0.92 | CDK4 (0.51) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL20987197 | 0.90 | EGFR (0.46) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL20987199 | 0.88 | CDK4 (0.53) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL22172140 | 0.88 | EGFR (0.46) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL21522745 | 0.88 | CDK4 (0.54) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL30309496 | 0.88 | EGFR (0.46) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL30888974 | 0.88 | CDK4 (0.54) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL30309451 | 0.88 | CDK4 (0.53) | CDK4CDK6CDK2CCND3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063436-A | Preparation method of arbeli | 山东铂源药业股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2019102492-A1 | CRYSTALLINE POLYMORPHS OF ABEMACICLIB | MYLAN LABORATORIES LIMITED (IN) | 2019-05-31 | — | — | WO | claimed |
| US-12577254-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | Signal Rx Pharmaceuticals, Inc. | 2026-03-17 | — | — | US | disclosed |
| EP-4077325-B1 | SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS | LUNELLA BIOTECH INC (CA) | 2026-03-11 | — | — | EP | disclosed |
| EP-4626423-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250304591-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS SELECTIVE CDK 4/6 INHIBITORS | LUNELLA BIOTECH INC (CA) | 2025-10-02 | — | — | US | disclosed |
| US-12358920-B2 | Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors | LUNELLA BIOTECH, INC. (CA) | 2025-07-15 | — | — | US | disclosed |
| US-12319690-B2 | Selective CDK 4/6 inhibitor cancer therapeutics | LUNELLA BIOTECH, INC. (CA) | 2025-06-03 | — | — | US | disclosed |
| EP-3398947-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-115023424-B | Selective CDK4/6 inhibitor type cancer therapeutic drug | 卢内拉生物技术有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20170173013-A1 | COMBINATION THERAPY FOR CANCER | LILLY CO ELI (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3110444-A1 | COMBINATION THERAPY FOR CANCER | Eli Lilly and Company (US) | 2017-01-04 | — | — | EP | disclosed |
| CN-105153119-A | Pyridylpyrimidyl amine compounds or pyridylpyridyl amine compounds and application thereof | GUANGZHOU KEQIN NEW MEDICINE DESIGN CO LTD | 2015-12-16 | — | — | CN | disclosed |
| WO-2015130540-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2015-09-03 | — | — | WO | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2379528-A1 | PROTEIN KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010075074-A1 | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | CDK4 26/4885CDK6 86/4885CDK2 47/4885 |
| US-12358920-B2 | Substituted pyrrolo[2,3-d]pyrimidines as selective CDK 4/6 inhibitors | CDK6, CDK4, CDKL4 | CDK4 2/4885CDK6 1/4885CDK2 9/4885 |
| US-20250304591-A1 | SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES AS SELECTIVE CDK 4/6 INHIBITORS | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885CDK2 11/4885 |
| US-12577254-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CHEK1, CDK1, CDK3 | CDK4 17/4885CDK6 8/4885CDK2 7/4885 |
| US-20170173013-A1 | COMBINATION THERAPY FOR CANCER | FLT4, KDR, FLT1 | CDK4 459/4885CDK6 1856/4885CDK2 2064/4885 |
| US-12319690-B2 | Selective CDK 4/6 inhibitor cancer therapeutics | CDK6, CDK4, CDKL4 | CDK4 2/4885CDK6 1/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.